Kestra Advisory Services’s Protalix BioTherapeutics PLX Stock Holding History

Kestra Advisory Services’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.7K	Hold	10,000	–	–	﹤0.01%	3092
2025 Q4	$18K	Sell	10,000 -1,000	-9%	-$2.04K	﹤0.01%	4520
2025 Q3	$24.4K	Buy	+11,000	New	+$17.9K	﹤0.01%	2878
2025 Q2	–	Sell	-44,500	Closed	-$114K	–	2951
2025 Q1	$114K	Buy	44,500 +30,500	+218%	+$72.8K	﹤0.01%	2573
2024 Q4	$26.3K	Sell	14,000 -2,000	-13%	-$2.83K	﹤0.01%	2633
2024 Q3	$16.3K	Hold	16,000	–	–	﹤0.01%	2536
2024 Q2	$18.7K	Hold	16,000	–	–	﹤0.01%	2591
2024 Q1	$20.2K	Buy	16,000 +4,500	+39%	+$6.72K	﹤0.01%	2430
2023 Q4	$20.5K	Hold	11,500	–	–	﹤0.01%	2246
2023 Q3	$19.1K	Hold	11,500	–	–	﹤0.01%	2083
2023 Q2	$23K	Buy	+11,500	New	+$27.4K	﹤0.01%	2075

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Kestra Advisory Services's PLX Position: Q1 2026 in Review

Kestra Advisory Services held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 10,000 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3092.

Kestra Advisory Services first reported a position in PLX in Q2 2023 and has held it in 11 quarters since. The position peaked at $114K in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Kestra Advisory Services held 10,000 shares of Protalix BioTherapeutics worth $21.7K as of Q1 2026.
Kestra Advisory Services left its Protalix BioTherapeutics share count unchanged in Q1 2026.
Protalix BioTherapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #3092 holding.
Kestra Advisory Services first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 11 quarters since.
Kestra Advisory Services's Protalix BioTherapeutics position peaked at $114K in Q1 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.